Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC.ACHV · Entity 5072 | Chief Commercial Officer | January 28, 2025 | January 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACHIEVE LIFE SCIENCES, INC.
Report date January 28, 2025 · Filed January 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2036-01-28 | Direct | 180,000 |
Reported balance
After 2026-01-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-28 · Grant · Acquired 180,000 · Balance 180,000 F1: The option will vest as to 1/4 of the total award on the first anniversary of January 28, 2026, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest as to 1/4 of the total award on the first anniversary of January 28, 2026, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 28, 2026 Filed Jan 30, 2026 21:08 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001193125-26-031795 · ownership.xml · derivative · entry 1 Xinos Jaime · CIK 0002041627 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2036-01-28 F1 · derivative.exercise_date: The option will vest as to 1/4 of the total award on the first anniversary of January 28, 2026, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 20:39 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionPerformance Restricted Stock Unit (PRSU) · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-113581 · ownership.xml · derivative · entry 4 Xinos Jaime · CIK 0002041627 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 20,000 shares Expires 2035-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Represents PRSUs previously reported on January 30, 2025 that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors. F4 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement. F7 · derivative.exercise_date: Pursuant to the terms of the award agreement governing the PRSU, the number of underlying shares of the Issuer's common stock that may ultimately vest ranges from 0% to 100% of the number of the PRSUs initially granted, subject to certain milestones being met during the measurement period. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 20:39 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionPerformance Restricted Stock Unit (PRSU) · Derivative | 49,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-113581 · ownership.xml · derivative · entry 3 Xinos Jaime · CIK 0002041627 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,000 shares Expires 2028-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement. F5 · derivative.exercise_date: Pursuant to the terms of the award agreement governing the PRSU, the total number of shares underlying the PRSU vest on the achievement of one of certain milestones. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 20:39 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | SaleCommon Stock | 20,854 | $2.77 | $57,765.58 |
DisclosureSEC source: 0000950170-25-113581 · ownership.xml · nonDerivative · entry 2 Xinos Jaime · CIK 0002041627 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,432 F2 · shares: Represents shares of common stock that have been sold by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the PRSUs. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.68 to $2.88 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 20:39 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionCommon Stock | 69,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-113581 · ownership.xml · nonDerivative · entry 1 Xinos Jaime · CIK 0002041627 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock acquired upon settlement of the performance restricted stock units ("PRSUs") listed in Table II. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 21:51 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantPerformance Restricted Stock Unit (PRSU) · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-011159 · ownership.xml · derivative · entry 1 Xinos Jaime · CIK 0002041627 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-01-28 F1 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement. F2 · derivative.exercise_date: Pursuant to the terms of the award agreement governing the PRSU, the number of underlying shares of the Issuer's common stock that may ultimately vest range from 0% to 100% of the number of the PRSUs initially granted, subject to certain milestones being met during the measurement period. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 21:41 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0000950170-25-005389 · ownership.xml · derivative · entry 1 Xinos Jaime · CIK 0002041627 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-01-13 F1 · derivative.exercise_date: The option will vest as to 1/4 of the total award on the first anniversary of December 6, 2024, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 21:45 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0000950170-24-134606 · ownership.xml · derivative · entry 1 Xinos Jaime · CIK 0002041627 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-12-06 F1 · derivative.exercise_date: The options vest 25% on the first anniversary of December 6, 2024 and thereafter in monthly installments over 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.